NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









MiNA Therapeutics

MiNA Therapeutics

Private
LondonHealthcare & Life Scienceshttps://minatx.com/

Last Round

Corporate Funding

Jul 6, 2021

Est. Valuation

$176.56M

Total Funding Raised

$90.73M

Company Overview

MiNA Therapeutics is a biotechnology company that develops small activating RNA (saRNA) therapeutics to restore or enhance gene function for the treatment of cancer and severe genetic diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Non-AI

Keywords

small activating RNAsaRNAgene activationRNA therapeuticsRNAabiotechnologyoncologyliver diseasedrug discoveryclinical-stage biotechgene expressionoligonucleotide therapyprecision medicinebiotech licensing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

MiNA Therapeutics Comparables

Compare MiNA Therapeutics with similar companies based on industry and business-model similarity.

MiNA Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Ractigen Therapeutics
85%
CAMP4
79%
Bristol Myers Squibb
71%

MiNA Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Corporate FundingJul 6, 2021
Series ASep 10, 2020
GrantNov 2, 2017
StrategicMay 3, 2017

Key People

Founding team and executive leadership

Robert Habib

CEO

Executive Team

Robin Wright FCA CSOP

Group Chief Financial Officer

Executive Team

MiNA Therapeutics Investors

Notable investors and investment history

MiNA Therapeutics investors
InvestorRounds
Innovate UKGrant
aMoonSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 12, 2025

    New data from sickle cell disease program presented at EHA 2025 Congress.

  • Jun 12, 2025

    Presented at the European Hematology Association 2025 Congress.

MiNA Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

MiNA Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about MiNA Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersLondon
Employee Range26
Year Founded2008
Last FundingJul 6, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.